Use of Targeted Agents Among Patients With R/R Follicular Lymphoma

At the 2024 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Joanna Rhodes, MD, MSCE, Rutgers Cancer Institute, New Brunswick, New Jersey, participated in a debate in which she discussed the use of novel therapies including targeted agents in the relapsed/refractory (R/R) follicular lymphoma (FL) treatment landscape.

“Overall, we know the mechanisms of action of these drugs. We know that they're safe, well tolerated, they're easy to give outside of an academic center. I believe that most patients when sequencing through therapies for R/R follicular lymphoma will encounter these drugs as part of their treatment regimens,” concluded Dr Rhodes.

Transcript:

Hi, I'm Dr. Joanna Rhodes. I'm the director of lymphoma at Rutgers Cancer Institute, and I'm here at LL&M 2024. In our session, we focused the debate [on] what's the correct second-line plus therapy for patients with R/R lymphoma.

We heard wonderful discussions from Dr. [Daniel] Landsberg regarding chimeric antigen receptor (CAR) T-cell therapy [and] from Dr. [Nina] Wagner Johnston regarding bispecific antibodies. I was tasked with discussing targeted agents for patients with R/R follicular lymphoma.

Some of the highlights from my talk include the role of zanubrutinib and obinutuzumab as a new set of agents that we can use for patients with R/R lymphoma with a well-tolerated safety profile and overall good efficacy, as well as further discussion of EZH2 inhibitors potentially being used in combinations either earlier or later in lines of therapy, as well as the use of immunomodulatory drugs (IMiDs) or immunomodulatory agents such as lenalidomide in the treatment paradigm for patients with R/R follicular lymphoma.

Overall, we know the mechanisms of action of these drugs. We know that they're safe, well- tolerated, [and] they're easy to give outside of an academic center. I believe that most patients when sequencing through therapies for R/R follicular lymphoma will encounter these drugs as part of their treatment regimens.

Source:

Rhodes J. Debate: How to Prioritize Therapy for Patients with R/R FL: Novel Agents Including BTKi, EZH2, iMIDS. Presented at Lymphoma, Leukemia & Myeloma Congress; October 16-19, 2024. New York, NY.